



Visual Disturbance as Presenting Feature and Macular Hole as Complication of Chronic Myeloid Leukemia

Rahul Bhargava^{1*} and Prachi Kumar²

¹Department of Ophthalmology, School of Medical Sciences & Research, Sharda University, India

²Department of Pathology, School of Medical Sciences & Research, Sharda University, India

Abstract

A 42-year old male presented with diminution of vision in left eye, weakness, and lethargy. On fundus examination (with +90 D lens), there was paramacular thickening with central macular and peripheral hemorrhages in left eye. Macular thickening was confirmed by Optical Coherence Tomography (OCT). Blood film demonstrated leukocytes with the presence of precursor cells of the myeloid lineage. Fluorescence in Situ Hybridization (FISH) revealed the presence of Philadelphia chromosome in 48% of inter phase cells studied. Patient was put on treatment with Imatinib tablet 400mg twice daily and treatment monitored. In the treatment phase, lamellar macular hole developed in the left eye at nine months. This case is being reported because of its unusual presentation and complication (Lamellar Macular Hole).

Keywords: Chronic myeloid leukemia; Lamellar macular hole; Visual disturbance

Introduction

Chronic Myelogenous Leukemia (CML) in blast phase rarely involve extramedullary sites like the skin and eyes [1,2]. Retina is the commonly involved ocular tissue with hemorrhages, sheathing, vascular tortuosity, and cotton wool spots in the chronic phase; however, visual disturbance may rarely be the presenting feature of CML [3,4].

Case Presentation

A lamellar macular hole complicating leukemic infiltration of sub-retinal tissues has never been reported. A 42-year old male presented to the out-patient department with painless and gradual diminution of vision, weakness, and fatigue for 2 months. His Corrected Distance Visual Acuity (CDVA) in right eye was 6/9 and in the left eye was 1/60. Slit lamp examination with a +90D lens showed flame-shaped hemorrhages, peri phlebitis and few cotton wool spots were seen in right eye (Figure 1a). In the left eye, there was a central macular hemorrhage surrounded by sub-retinal leukemic infiltration, thickening along with scattered dot and blot hemorrhages (Figure 1b). Increased macular thickness in the left eye was confirmed on optical coherence tomography (Figure 2a). The white blood cell count was $1.4 \times 10^9/\text{mm}^3$ and hemoglobin was 9.4 mg/dl. The blood film demonstrated the presence of precursor cells of the myeloid lineage (Figure 2c). Chromosomal analysis with karyotyping of peripheral blood specimen was performed; all 20 metaphases analyzed were abnormal and showed t(9;22) which were consistent with CML (Figure 2d). Specimen was again studied for Philadelphia chromosome (t(9;22) q34; q11) by Fluorescence in Situ Hybridization (FISH); 200 cells were studied using dual fusion DNA probes. Philadelphia chromosome was present in 48% of inter phase cells studied. The patient was referred to the regional cancer institute and was put on treatment with Imatinib tablets 400mg twice daily. The patient was followed at 3-monthly intervals at the cancer institute and at 6 monthly intervals in ophthalmic OPD. At first follow-up visit (9 months), CDVA was 6/12 in right eye and 6/36 in left eye. On +90D examination, a fibrovascular band was seen extending into the vitreous from the macula. However, the patient did not complain any symptoms suggestive of vitreo-macular traction like distortion, metamorphopsia or micropsia. At 12 months, although there was complete resolution of all ophthalmic lesions with diffuse pigmentation around the macula, the patient developed a lamellar macula hole in the left eye (Figure 2b). The corrected vision was 6/6 in the right eye and 6/60 in the left eye. There was complete hematological remission at 18 months. The patient has been on regular follow up for two years without any significant peripheral blood findings or relapse. Patient has tolerated Imatinib well and has not reported any adverse effect till date.

OPEN ACCESS

*Correspondence:

Rahul Bhargava, Department of Ophthalmology, School of Medical Sciences & Research, Sharda University, B2-004, Ananda Apartments, Sector 48, Noida, UP, 201301, India, Tel: +919999055223; E-mail: brahul_2371@yahoo.co.in

Received Date: 07 Dec 2017

Accepted Date: 14 Jan 2018

Published Date: 18 Jan 2018

Citation:

Bhargava R, Kumar P. Visual Disturbance as Presenting Feature and Macular Hole as Complication of Chronic Myeloid Leukemia. *J Clin Ophthalmol Eye Disord.* 2018; 2(1): 1021.

Copyright © 2018 Rahul Bhargava.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1: a: Fundus photograph showing multiple diffuse retinal hemorrhages with cotton wool spots and phlebitis. b: Fundus photograph showing leukemic infiltration and central macular hemorrhage (arrow). c: Fundus photograph showing complete resolution of hemorrhages in right eye. d: Fundus photograph showing lamellar macular hole and diffuse macular pigmentation.




Figure 2: a: Optical coherence tomography showing increased macular thickness. b: Optical coherence tomography showing lamellar macular hole (arrow). c: Peripheral blood film showing precursor cells of myeloid lineage. d: Karyotype showing Philadelphia Chromosome.

Discussion

Approximately, 40% patients with CML are asymptomatic, diagnosed on the basis of abnormal counts and most patients present in the chronic phase (range 85-97%). The median age at presentation

in India is a decade younger as compared to western countries (range 32-42 years) [5,6]. Splenomegaly is the most commonly reported symptom, followed by hepatomegaly, weakness and fatigue; in the present study, sudden diminution of vision was the presenting symptom, due to macular hemorrhage. The treatment response to Imatinib is variable due to population heterogeneity and about 91-97% patients achieve Complete Hematological Response (CHR) and 20-93 % Complete Cytogenetic Response (CCyR) [6]. Skin pigmentation, anemia and thrombocytopenia have been the commonly reported complications secondary to Imatinib therapy. Lamellar macular hole as a complication of CML has not been reported. The probable cause was vitreo-macular traction on the macula by the fibrous band in the vitreous; these bands often form due to fibrovascular activity in the retina following hemorrhages [7].

References

1. Talcott KE, Garg RJ, Garg SJ. Ophthalmic manifestations of leukemia. *Curr Opin Ophthalmol.* 2016;27:545-51.
2. Mandić BD, Potocnjak V, Bencić G, Mandić Z, Pentz A, Hajnzić TF. Visual loss as initial presentation of chronic myelogenous leukemia. *Coll Antropol.* 2005;29(1):141-3.
3. Huang PK, Sanjay S. Visual Disturbance as the first Symptom of Chronic Myeloid Leukemia. *Middle East African Journal of Ophthalmology.* 2011;18:336-8.
4. Tardieu S, Brun-Strang C, Berthaud P, Michallet M, Guilhot F, Rousselot P, et al. Management of chronic myeloid leukemia in France: a multi-centered cross-sectional study on 538 patients. *Pharmacoepidemiol Drug Saf.* 2005;14(8):545-53.
5. Bhutani M, Kochupillai V. Hematological malignancies in India, in Kumar L (editor): *Progress in Hematologic Oncology.* Pub. The Advanced Research Foundation New York, New York. 2003;10.
6. Bansal S, Prabhash K, Parikh P. Chronic myeloid leukemia data from India. *Indian J Med Paediatr Oncol.* 2013;34:154-8.
7. Nava U, Cereda MG, Bottoni F, Preziosa C, Pellegrini M, Giani A, et al. Long-term follow-up of fellow eye in patients with lamellar macular hole. *Graefes Arch Clin Exp Ophthalmol.* 2017;255(8):1485-92.